CINECA IRIS Institutional Research Information System

MENCONI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.670
AS - Asia 1.227
EU - Europa 1.099
SA - Sud America 167
AF - Africa 77
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.245
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.603
SG - Singapore 445
CN - Cina 338
SE - Svezia 283
IT - Italia 231
HK - Hong Kong 225
DE - Germania 167
BR - Brasile 140
GB - Regno Unito 76
BG - Bulgaria 75
FR - Francia 69
CA - Canada 45
VN - Vietnam 45
FI - Finlandia 43
AT - Austria 38
CI - Costa d'Avorio 38
IN - India 38
RU - Federazione Russa 37
TR - Turchia 34
JP - Giappone 22
SN - Senegal 21
UA - Ucraina 17
NL - Olanda 15
IQ - Iraq 13
BD - Bangladesh 12
SA - Arabia Saudita 11
MX - Messico 10
AR - Argentina 9
PL - Polonia 8
BE - Belgio 7
ES - Italia 7
IE - Irlanda 7
ZA - Sudafrica 7
ID - Indonesia 5
PH - Filippine 5
PK - Pakistan 5
PS - Palestinian Territory 5
AU - Australia 4
LT - Lituania 4
MA - Marocco 4
UZ - Uzbekistan 4
VE - Venezuela 4
AZ - Azerbaigian 3
CL - Cile 3
CO - Colombia 3
EC - Ecuador 3
EG - Egitto 3
PA - Panama 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BS - Bahamas 2
CH - Svizzera 2
CR - Costa Rica 2
DZ - Algeria 2
KR - Corea 2
LB - Libano 2
NP - Nepal 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EU - Europa 1
HN - Honduras 1
HR - Croazia 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
PY - Paraguay 1
RS - Serbia 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 5.245
Salva come PNG Salva come JPEG
Città #
Dallas 353
Ashburn 325
Woodbridge 262
Hong Kong 222
Fairfield 219
Singapore 206
Houston 166
Santa Clara 144
Chandler 139
Ann Arbor 107
Seattle 92
Beijing 80
Sofia 75
Wilmington 72
Shanghai 71
New York 66
Serra 66
Cambridge 61
Munich 59
Los Angeles 58
Florence 40
Abidjan 38
Boardman 35
London 34
Vienna 34
Ottawa 33
Princeton 32
Lawrence 27
Bremen 26
Frankfurt am Main 25
Medford 24
Turku 23
Dakar 21
Pisa 19
Tokyo 19
Dong Ket 18
Istanbul 18
Des Moines 17
Redondo Beach 17
Dearborn 15
Marseille 15
Nanjing 14
Ogden 14
Lancaster 13
Chicago 12
Buffalo 11
Düsseldorf 11
Chennai 10
Denver 9
Izmir 9
Atlanta 8
Helsinki 8
Nanchang 8
Orem 8
Rome 8
San Diego 8
São Paulo 8
Baghdad 7
Brussels 7
Fuzhou 7
Kunming 7
Lucca 7
Warsaw 7
Changsha 6
Guangzhou 6
Ho Chi Minh City 6
Manchester 6
Montreal 6
Riyadh 6
Tianjin 6
Dublin 5
Gaza 5
Hebei 5
Houten 5
Jacksonville 5
Jinan 5
Johannesburg 5
Milan 5
Paris 5
Poplar 5
Portsmouth 5
Rio de Janeiro 5
Stockholm 5
Aosta 4
Belo Horizonte 4
Cagliari 4
Dhaka 4
Jüchen 4
Kent 4
Mexico City 4
Nuremberg 4
Ossé 4
San Francisco 4
Taiyuan 4
Zhengzhou 4
Amsterdam 3
Baku 3
Basra 3
Brooklyn 3
Caracas 3
Totale 3.744
Salva come PNG Salva come JPEG
Nome #
Natural history of graves’ orbitopathy after treatment 253
Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? 210
Role of the underlying thyroid disease on the phenotype of graves' orbitopathy in a tertiary referral center 204
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 199
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study 189
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 172
Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO) 171
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY 165
Optic neuropathy in 2 thyroidectomized patients with moderate to severe Graves’ ophthalmopathy following L-thyroxine withdrawal prior to radioiodine treatment for thyroid carcinoma 162
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 161
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study 154
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 150
PREGO ( presentation of Graves' orbitopathy) study: Changes in referral patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012 142
Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ Orbitopathy – A randomized, observer blind, multicenter trial 139
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study 133
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 132
Hypothyroidism Due to L-T4 Withdrawal Can Precipitate Optic Neuropathy in Patients with Moderate to Severe Graves' Ophthalmopathy: Report on Two Cases 124
null 121
Selenium in Graves Hyperthyroidism and Orbitopathy 118
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 118
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocols 112
In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' orbitopathy 110
Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimus 105
null 100
null 95
null 93
null 91
null 88
Sirolimus as a second-line treatment for Graves' orbitopathy 87
Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy 87
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy 86
IgG4 serum levels in Graves' orbitopathy 72
Long-term outcome of Graves’ orbitopathy following treatment with sirolimus 71
Role of genetics and epigenetics in Graves’ orbitopathy 70
null 70
Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves' Orbitopathy: A Retrospective Cohort Study 68
Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy 66
null 65
Insights Into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy 61
An update on the medical treatment of Graves' hyperthyroidism. 59
Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study 58
null 57
Diagnosis and classification of Graves' disease 56
Insights Into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy 55
Absence of a relationship between vitamin D and Graves’ orbitopathy 54
Role of genetic and non-genetic factors in the etiology of Graves' disease 54
Graves disease: latest understanding of pathogenesis and treatment options 51
Absence of a relationship between vitamin D and Graves’ orbitopathy 44
Total thyroid ablation in Graves' orbitopathy 44
null 3
null 1
null 1
Totale 5.351
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.630
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.630
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021129 0 0 0 0 0 9 20 18 23 18 14 27
2021/2022446 1 6 5 41 88 49 3 18 65 68 3 99
2022/2023580 66 119 49 42 42 48 5 41 118 0 48 2
2023/2024218 7 10 24 8 26 58 4 16 3 3 34 25
2024/20251.348 10 33 16 56 119 137 94 47 130 174 168 364
2025/20261.243 164 243 333 166 216 121 0 0 0 0 0 0
Totale 5.351